Latest Breaking News On - Gastrointestinal medical oncology service - Page 1 : comparemela.com

Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers

Domvanalimab plus zimberelimab with chemotherapy demonstrated a positive overall response rate and 6-month progression free survival rate for patients with upper gastrointestinal cancers.

United statesYelenay janjigianArcus biosciences incDomvanalimab gilead sciences incGilead sciences incAmerican societyClinical oncology monthly plenaryGastrointestinal medical oncology serviceMemorial sloan kettering cancer centerArcus biosciences

FinancialNewsMedia com: Global Anal Cancer Market Size Expected to Reach $1 24 Billion In 2028 as Treatments Advance

FinancialNewsMedia com: Global Anal Cancer Market Size Expected to Reach $1 24 Billion In 2028 as Treatments Advance
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSan diegoBristol myers squibbSamit hirawatYelenay janjigianDirk arnoldMatt coffeyInternational multidisciplinary anal cancer conferenceGlobal drug developmentCenters for disease controlPhysician of the gastrointestinal medical oncology serviceMemorial sloan kettering cancer centerArcus biosciences incDrug administrationPfizer incOncolytics biotech

Arcus (RCUS) and Gilead (GILD) Report New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen

Arcus (RCUS) and Gilead (GILD) Report New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesYelenay janjigianPhysician of the gastrointestinal medical oncology serviceMemorial sloan kettering cancer centerArcus biosciences incAmerican society of clinical oncologyGilead sciences incGilead sciencesArcus biosciencesAmerican societyClinical oncologyMonthly plenary seriesChief attending physicianGastrointestinal medical oncology service

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Foster cityUnited statesYelenay janjigianExchange commissionGilead sciencesAmerican society of clinical oncologyArcus biosciences incProduct serviceMemorial sloan kettering cancer centerGilead public affairsPhysician of the gastrointestinal medical oncology serviceGilead sciences incContaining regimenFirst line treatmentArcus biosciencesAmerican society

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-

– Preliminary data from Arm A1 of the Phase 2 EDGE-Gastric study showed promising ORR and six-month PFS results, irrespective of PD-L1 expression –– Domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first to market for these cancers –– Detailed.

United statesFoster cityJacquie rossMeaghan smithHolli kolkeyYelenay janjigianGilead public affairsArcus biosciences incMemorial sloan kettering cancer centerAmerican society of clinical oncologyGilead sciencesPhysician of the gastrointestinal medical oncology serviceExchange commissionGilead sciences incPlenary seriesArcus biosciences